Company Description
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.
In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 1990 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 378 |
| CEO | Amir London |
Contact Details
Address: 2 Holtzman St., Science Park Rehovot, L3 7670402 Israel | |
| Phone | 97289406472 |
| Website | kamada.com |
Stock Details
| Ticker Symbol | KMDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001567529 |
| CUSIP Number | M6240T109 |
| ISIN Number | IL0010941198 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amir London | Chief Executive Officer |
| Chaime Orlev | Chief Financial Officer |
| Eran Nir | Chief Operating Officer |
| Jon R. Knight | Vice President of US Commercial Operations |
| Boris Gorelik | Vice President of Business Development and Strategic Programs |
| David Tsur | Co-Founder and Independent Deputy Chairman of the Board |
| Nir Livneh B.A., L.L.B. | Vice President, General Counsel and Corporate Secretary |
| Hanni Neheman | Vice President of Marketing and Sales |
| Liron Reshef | Vice President of Human Resources |
| Shavit Beladev | Vice President of Kamada Plasma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 28, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 28, 2023 | 6-K | Report of foreign issuer |
| Dec 19, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 6, 2023 | 6-K | Report of foreign issuer |
| Nov 13, 2023 | 6-K/A | Filing |